Juvenile Idiopathic Arthritis
Conditions
Brief summary
The aim of our study is to compare the immune function of patient treated with DMARD (methotrexate), or tumor necrosis factor (TNF)-alpha inhibitor (adalimumab) to healthy children. The study consists of three parts. In each part physical examination and routine laboratory tests are done. At the first examination flow cytometry analysis is performed, after that the participants are immunized with influenza (3Fluart) vaccine. At part two and three further flow cytometry is carried out and seroconversion is measured.
Interventions
BIOLOGICALInfluenza vaccine, Immune function
Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
Sponsors
University of Pecs
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
Yes
Inclusion criteria
* JIA (oligoarticular, polyarticular) treated with MTX or MTX/adalimumab * Healthy controls
Exclusion criteria
* Children with infection * Children with active JIA disease * JIA other than oligoarticular, polyarticular type
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparing the healthy population and the JIA participants treated with DMARD (MTX) or TNF-alpha inhibitor (adalimumab) | 12-14 weeks | Analysing T and B cells (%, /microL) by flow cytometry. |
| Immune response to influenza vaccine, the rate of seroconversion | 12-14 weeks | Measuring seroconversion after influenza vaccine (IU) |
Countries
Hungary
Outcome results
None listed